WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the initial clinical data on BGB-A317 are scheduled to be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. BGB-A317 is a humanized monoclonal antibody against the immune checkpoint inhibitor PD-1. The ASCO Annual Meeting will take place June 3-7, 2016 in Chicago, Illinois. Details of the poster presentation are provided below.
Title: A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors
Authors: Jayesh Desai, Ben Markman, Shahneen Kaur Sandhu, Hui Kong Gan, Michael Friedlander, Ben Tran, Tarek Meniawy, Vishal Boolell, Duncan Colyer, Christie Norris, Malaka Ameratunga, Jason Yang, Kang Li, Lai Wang, Lusong Luo, Zhen Qin, Michael Millward
Presenter: Dr. Jayesh Desai
Session: Developmental Therapeutics – Immunotherapy
Date: Sunday, June 5, 2016
Time: 8:00 - 11:30 AM CDT
Location: Hall A
Poster Board: #388
BGB-A317 is a humanized monoclonal antibody that belongs to a new class of immuno-oncology agents known as immune checkpoint inhibitors. It is designed to bind to PD-1, a cell surface receptor that plays an important role in downregulating the immune system by preventing the activation of T-cells. BGB-A317 has high affinity and specificity for PD-1 and differs from the currently approved PD-1 antibodies with the ability to bind Fc gamma receptor I specifically engineered out.
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 215 scientists, clinicians and staff in China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s existing product candidates and research programs. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates, the clinical results for its drug candidates, which may not support further development, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, BeiGene's ability to achieve market acceptance in the medical community necessary for commercial success, BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs, BeiGene's reliance on third parties to conduct preclinical studies and clinical trials, and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled "Risk Factors" in our most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
Lucy Li, Ph.D.
Source: BeiGene, LTD.